Headache & Pain

Filter Your Results

 

News

 

Biomarkers Available to Speed Diagnosis of Fibromyalgia

Wednesday, March 07, 2018—Iquity (Nashville, Tennessee) has announced the release of IsolateFibromyalgia, an RNA analysis of blood samples, for the fast and accurate detection of fibromyalgia syndrome.…

First Patient Enrolled in Phase 3 Clinical Trial of Rimegepant for Acute Migraine Treatment

Tuesday, March 06, 2018—Biohaven Pharmaceutical (New Haven, CT) announced today the first patient enrollment in their phase 3 clinical trial of rimegepant (Zydis) for the acute treatment of migraine.…

Biosimilar Being Developed for Botox

Thursday, March 01, 2018—In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on th…

Migraine Sufferers May Be at Greater Risk of Ischemic Stroke

Tuesday, February 20, 2018—Stroke, a journal of the American Heart Association published an article by Alessandro Pezzine, Giorgio Busto, Marialuisa Zedde, et al., (Stroke. 2018:published online Feb 20)…

First Prospective Registry Shows Efficacy of Neuromodulation of the Sphenopalatine Ganglion for Treating Cluster Headache

Thursday, January 25, 2018—On January 25, 2018, The Journal of Headache and Pain published one-year results from an open-label registry trial, Pathway R-1, evaluating the efficacy of sphenopalatine-gang…

PROMISE Phase 3 Trial for Chronic Migraine Prevention Meets Primary and All Key Secondary Endpoints; Shows Reduction in Migraine Risk

Monday, January 08, 2018—January 8, 2018--Alder Biopharmaceutical reported that their injectable calcitonin-gene-related peptide (CGRP)-inhibitor eptinezumab, in phase 3 clinical trials, reduced month…

Once-Daily Lyrica Formulation Wins FDA Approval

Thursday, October 12, 2017—The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic periphera…

FDA Approves Intellis Device for Intractable Pain

Wednesday, September 20, 2017—The FDA has approved the Intellis platform (Medtronic) for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitati…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC